Phase 2 N=24 Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Time to Progression (TTP) — 3.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=99 Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants
Influenza Infection
Primary: Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 6-35 Months Old Group — 3; 4; 12; 2 participants
Phase 2 N=26 Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
Type 2 Diabetes Mellitus
Primary: AUC (0-24) of Plasma Metformin — 7771; 5559; 7757 ng*h/mL — p=0.0018
Phase 2 N=36 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Neurofibromatosis
Primary: Percent Change From Baseline in Tumor Volume at 6 Months — 17 percentage change of tumor volume
Phase 2 N=100 A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) — 99 percentage of participants
Phase 2 N=77 OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
Milk Allergy
Primary: Percentage of Subjects in the Xolair® (Omalizumab) Group vs. Placebo Group Developing Clinical Tolerance to Milk — 46.4; 34.5 Percent of participants — p=0.42
Phase 2 N=72 A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
Methamphetamine Dependence, Treatment Seeking
Primary: Methamphetamine Abstinence
Phase 2 N=67 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
Prostate Cancer
Primary: Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25 — 92.5 Percentage of Participants
Phase 2 N=57 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants
Phase 2 N=25 A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 16 Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale — 55.2; 59.0…
Phase 2 N=195 Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
HIV Infections
Primary: Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV — 1; 4; 0; 0 participants
Phase 2 N=111 Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis
Ulcerative Colitis
Primary: Clinical Response at Week 8 Based on Mayo Score — 37.5; 32.7 Percentage of responders — p=0.4062
Phase 2 N=208 Code Status Video in the Intensive Care Unit: Video Assisted Patient Education
Critical Illness
Primary: 12 Question Resuscitation Status Survey (Question 4 Has 4 Sub-questions) — 6.5; 9 points
Phase 2 N=243 Selegiline Patch for Treatment of Nicotine Dependence
Tobacco Use Disorder
Primary: Expired-air Carbon Monoxide Confirmed Smoking Abstinence — 24; 25 participants not smoking
Phase 2 N=189 S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 1.8; 1.3; 1.4; 1.4 Months